Edition:
United Kingdom

Zafgen Inc (ZFGN.OQ)

ZFGN.OQ on NASDAQ Stock Exchange Global Select Market

3.79USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$3.79
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
20,265
52-wk High
$5.43
52-wk Low
$3.16

Chart for

About

Zafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company's lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including... (more)

Overall

Beta: -1.40
Market Cap(Mil.): $94.27
Shares Outstanding(Mil.): 27.48
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Zafgen reports Q3 loss per share $0.46

* Q3 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S

07 Nov 2017

BRIEF-Zafgen appoints Jeffrey Hatfield as CEO

* Zafgen appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to continue as president, appointed chief scientific officer

10 Oct 2017

BRIEF-Zafgen initiates Phase 2 clinical trial for ZGN-1061

* Zafgen initiates Phase 2 clinical trial for ZGN-1061 in patients with Type 2 diabetes Source text for Eikon: Further company coverage:

12 Sep 2017

BRIEF-Zafgen Inc files for a potential mixed shelf offering of up to $150 mln

* Zafgen Inc files for a potential mixed shelf offering of up to $150 million - SEC filing Source text: (http://bit.ly/2vkwJqL) Further company coverage:

09 Aug 2017

BRIEF-Zafgen Q2 loss per share $0.49

* Q2 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

08 Aug 2017

Earnings vs. Estimates